Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-12

Study Completion Date

2029-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Both neoadjuvant chemoradiotherapy (CROSS) and neoadjuvant chemotherapy (FLOT) have demonstrated overall survival benefit over surgery alone in esophageal and esophagogastric junction (EGJ) cancer. Despite these survival gains, the prognosis remains poor, especially in patients with nodal-positive adenocarcinoma (cN+ AC) (5-year survival 36%, compared to 55% for cN0). This highlights the need for more effective treatment options, and justifies treatment intensification in these patients.

The aim of this study is to determine the efficacy and feasibility of TNT FLOT-CROSS and TNT CROSS-FLOT in patients with resectable, cN+ AC of the esophagus or EGJ.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study hypothesizes that the benefits of the locoregional control of CROSS combined with the systemic effect of FLOT leads to better disease control and survival in cN+ AC patients. This Total Neoadjuvant Treatment (TNT) strategy was found to be feasible in the previous TNT-OES-1 trial. The optimal sequence of CROSS and FLOT is yet unknown. Therefore, the hypothesis of this study is that the progression-free survival (PFS) of patients treated with TNT FLOT-CROSS and TNT CROSS-FLOT will be ≥10% compared to the PFS after CROSS in an appropriate historical cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Adenocarcinoma of the Esophagus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Total Neoadjuvant Therapy Chemotherapy Chemoradiotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Arm A: FLOT-CROSS Arm B: CROSS-FLOT

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TNT FLOT-CROSS

Patients allocated to the TNT FLOT-CROSS arm will be treated with 4 cycles of FLOT chemotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to CROSS chemoradiotherapy.

Group Type EXPERIMENTAL

FLOT-CROSS or CROSS-FLOT

Intervention Type DRUG

Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT

TNT CROSS-FLOT

Patients allocated to the TNT CROSS-FLOT arm will be treated with CROSS chemoradiotherapy followed by a response evaluation consisting of a CT-scan and upper endoscopy with bite-on-bite biopsies of the primary tumor site and of any other suspected lesions in the esophagus. Patients with distant metastases will go off-study. All other patients will proceed to FLOT chemotherapy.

Group Type EXPERIMENTAL

FLOT-CROSS or CROSS-FLOT

Intervention Type DRUG

Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FLOT-CROSS or CROSS-FLOT

Randomization between TNT FLOT-CROSS and TNT CROSS-FLOT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients with cT2-4aN+M0 resectable adenocarcinoma of the oesophagus or EGJ (Siewert type I-II) according to the 8th edition of the Union for International Cancer Control (UICC) TNM classification for Esophageal Cancer who are planned to undergo nCRT or FLOT (43). In case of stage cT4a, curative resectability has to be explicitly verified by the multidisciplinary tumor board.

Clinical N+ status should be determined by EUS or 18F-FDG PET/CT. Clinical M0 status must be determined by 18F-FDG PET/CT.

* Maximum of 4 cm ingrowth in the cardia, measured by upper endoscopy.
* In case of tumor and/or lymph node involvement below the diaphragm, the most proximal involved lymph node station cannot be higher than N7 (Appendix C).
* In case of no tumor or lymph node involvement below the diaphragm, the most proximal involved lymph node station cannot be higher than N4 (Appendix C).
* Age ≥ 18 years. For patients aged 70 years or older, a geriatric screening tool (G8) should be used to assess functioning across the domains. If a patient has a score of 14 or lower on the G8, a comprehensive geriatric assessment (CGA) should be done prior to inclusion (Appendix D).
* No prior abdominal, thoracic or cervical radiotherapy overlapping with the CROSS irradiation fields.
* No prior cytotoxic chemotherapy for oesophageal cancer.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 (44).
* Weight loss \<10%.
* Adequate cardiac and respiratory function (cardiac or pulmonary function tests such only necessary in symptomatic patients).
* Adequate bone marrow function (White Blood Cells \>3x109/L; Haemoglobin \>5.5 mmol/L; platelets \>100x109/L). In the event of transfusions, the last red blood cell transfusion should be more than 2 weeks before inclusion.
* Adequate renal function (Glomerular Filtration Rate \>50 ml/min) or serum creatinine ≤1.5 x upper limit of normal (ULN) and adequate liver function (total bilirubin \<1.5x Upper Level of Normal (ULN); Aspartate transaminase (AST) \<2.5x ULN and Alanine transaminase (ALT) \<3x ULN.
* A negative serum pregnancy test in women of child-bearing potential during screening period.
* Use of adequate contraception during the study up to 3 months after the end of the study.
* Written informed consent and ability to understand the nature of the study and the study-related procedures and to comply with them.

Exclusion Criteria

* Patients with tumours of squamous, adenosquamous or other non-adenocarcinoma histology.
* Patients who are eligible for and want to participate in the TRAP-2 trial (NCT05188313)
* Clinically significant (active) cardiac disease (e.g. symptomatic coronary artery disease of myocardial infarction within the last 12 months) or lung disease (forced expiratory volume in one second (FEV1) \<1.5L).
* Peripheral neuropathy grade \>1, according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (37).
* Homozygous DPYD genotype (tested for \*2A, \*13, 2846A\>T, and 1236G\>A)
* Pregnant and lactating women, or patients of reproductive potential who are not using effective contraception. If barrier contraceptives are used, they must be continued by both sexes throughout the study.
* Other active malignancies with a prognosis interfering with that of oesophageal cancer.
* Expected lack of compliance with the protocol.
* Limitations such as language barriers, dementia, or altered mental status that make it impossible for the participant to understand the study, provide informed consent, and complete quality of life questionnaires. Participants who do not speak the primary study language may still be included if the study information is adequately translated or explained (e.g., read aloud in their native language) and they demonstrably understand the study procedures.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. B. (Bianca) Mostert

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bianca Mostert, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Erasmus Medical Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.